The FDA has released today documents in which U.S. drug reviewers say that an AstraZaneca drug to treat patients with inoperable thyroid cancer carries “substantial toxicity”. Astrazaneca developed an experimental cancer drug that at one point was the hope for cancer treatments but it was evidenced that it didn’t help in lung cancer patients.
According to the FDA staff, they will have a public meeting on Thursday where they will ask an advisory panel to consider other side effects from
Tidak ada komentar:
Posting Komentar